Group 1 - Insight Molecular Diagnostics Inc. (iMDx) announced participation in investor conferences hosted by H.C. Wainwright and Lake Street Capital Markets [1] - The H.C. Wainwright 27th Annual Global Investment Conference will take place on September 8-9, 2025, featuring a company presentation on September 8 at 5:00 pm ET [1] - The Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (BIG9) is scheduled for September 11, 2025, with a format of one-on-one meetings [1] Group 2 - Insight Molecular Diagnostics is focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [2] - The company holds several trademarks, including GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ [2]

Core Insights - Insight Molecular Diagnostics, Inc. (iMDx) aims to democratize access to molecular diagnostics, particularly in transplant monitoring, by developing self-run testing kits for hospitals [3][4][7] - The company recently rebranded from Oncocyte to Insight Molecular Diagnostics to better reflect its mission [4][8] - iMDx's first commercial focus is on measuring donor-derived cell-free DNA to monitor transplanted organ health [4][5] Company Strategy - iMDx is working on a regulatory pathway to obtain FDA clearance for its diagnostic tests, with a submission expected by the end of 2025 and potential clearance in 2026 [6] - The company has a research-use-only version of its kit currently utilized by 10 centers globally [5] - iMDx's strategy includes increasing visibility with investors as it approaches key regulatory milestones [6] Market Position - The company has relocated its headquarters from Irvine, California, to Nashville, Tennessee, and changed its NASDAQ symbol effective June 18, 2025 [8] - iMDx's mission is to improve patient outcomes by making advanced molecular diagnostic testing more accessible [4][7]

Company Announcements - Insight Molecular Diagnostics, or iMDx, will report its second quarter 2025 financial results after the market closes on August 11, 2025 [1] - A live Zoom webinar will be held on the same day at 2:00 pm PT / 5:00 pm ET to discuss the financial results, followed by a Q&A session [1] - An archived replay of the webinar will be available on iMDx's investor relations website after the call concludes [2] Upcoming Events - CEO Josh Riggs and CFO Andrea James will attend the 10th Annual Needham Virtual MedTech & Diagnostics Conference on August 12, 2025 [3] - The conference will take place virtually from August 11-12, 2025, and investors can book one-on-one meetings with management through their Needham sales representative [3][4] Company Background - Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corp., is focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [4] - The company moved its headquarters from Irvine, California, to Nashville, Tennessee, in June 2025, with a new NASDAQ symbol effective June 18 [5]

Core Insights - Oncocyte Corp. will participate in the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025, with CEO Josh Riggs and CFO Andrea James attending [1][3] - The focus of the discussion will be on Oncocyte's innovative diagnostic technologies and the progress towards commercializing a regulated organ transplant rejection monitoring test kit [2][4] Company Overview - Oncocyte is a diagnostics technology company that provides tests aimed at enhancing clarity and confidence for physicians and patients [4] - Key products include: - VitaGraft™: A clinical blood-based solid organ transplantation monitoring test - GraftAssure™: A research use only (RUO) blood-based solid organ transplantation monitoring test - DetermaIO™: A gene expression test for predicting response to immunotherapies - DetermaCNI™: A blood-based monitoring tool for assessing therapeutic efficacy in cancer patients [4][5]